MDT-AP-3168
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 125.88
- os_event
- true
- age_years
- 32.91
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.421497556
- umap2_2d
- -11.25002513
- umap1_3d
- -3.77757829
- umap2_3d
- 0.316363853
- umap3_3d
- 6.093490649
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.400
- INTERFERON_ALPHA_RESPONSE+0.380
- MYC_TARGETS_V2+0.380
- INTERFERON_GAMMA_RESPONSE+0.360
- UV_RESPONSE_DN+0.350
- PROTEIN_SECRETION+0.320
- NOTCH_SIGNALING+0.300
- MITOTIC_SPINDLE+0.290
Top 10 suppressed
- APICAL_SURFACE-0.280
- MYOGENESIS-0.280
- UV_RESPONSE_UP-0.250
- CHOLESTEROL_HOMEOSTASIS-0.220
- ESTROGEN_RESPONSE_LATE-0.190
- PANCREAS_BETA_CELLS-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- KRAS_SIGNALING_DN-0.170
- HEME_METABOLISM-0.130
- COAGULATION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_D7XRFE0R | Diffuse intrinsic pontine glioma | — | 0.853 |
| 2 | MDT-AP-3324 | Med | Medulloblastoma | 0.846 |
| 3 | 64F4FE1B-1B96-49CC-B4E9-454D971DB7BC | — | — | 0.845 |
| 4 | SRR934774 | — | — | 0.814 |
| 5 | SRR934919 | — | — | 0.811 |
| 6 | SRR934878 | — | — | 0.806 |
| 7 | SRR934882 | — | — | 0.800 |
| 8 | 8F64E7A6-DEE2-426E-B843-DE4D73ECD667 | — | — | 0.800 |
| 9 | SRR934922 | — | — | 0.793 |
| 10 | SRR934957 | — | — | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.070 | Inavolisib | — uncovered |